Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 3/20 | 0.71 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.71 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.71 |
| ▸ | IGF1R | P08069 | 14/20 | 0.62 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17544877 | 0.87 | CDK1 (0.68) | ULK1PDK1ULK2IGF1RCDK1 | |
| SCHEMBL30099800 | 0.83 | ULK1 (1.00) | ULK1PDK1ULK2IGF1RNTRK1 | |
| SCHEMBL15256327 | 0.79 | IGF1R (0.79) | IGF1RNTRK1 | |
| SCHEMBL20438003 | 0.79 | NEK1 (0.67) | ULK1PDK1ULK2IGF1R | |
| SCHEMBL19654400 | 0.78 | ULK1 (0.72) | ULK1ULK2CDK1 | |
| SCHEMBL15217712 | 0.78 | IGF1R (0.57) | IGF1RNTRK1 | |
| SCHEMBL19654471 | 0.78 | IGF1R (0.60) | ULK1IGF1RNTRK1 | |
| SCHEMBL15580694 | 0.77 | IGF1R (1.00) | IGF1RNTRK1 | |
| SCHEMBL15109533 | 0.76 | IGF1R (0.79) | IGF1R | |
| SCHEMBL15217683 | 0.76 | NTRK1 (0.72) | IGF1RNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | ULK1 1/4885PDK1 382/4885ULK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.